

News Article downloaded from - <http://www.bioportfolio.com> on Tuesday, November 24, 2009
Read [Reportlinker Adds Competitor Analysis: VEGF and VEGF-R Agonists and Antagonists](http://www.bioportfolio.com/news/Reportlinker-Adds-Competitor-Analysis:-VEGF-and-VEGF-R-Agonists-and-Antagonists) on
BioPortfolio.com (<http://www.bioportfolio.com/news/Reportlinker-Adds-Competitor-Analysis:-VEGF-and.html>)

Reportlinker Adds Competitor Analysis: VEGF and VEGF-R Agonists and Antagonists

Friday 16th of October 2009 10:01

-- additional comments with a hyperlink leading to the source of information.

Index

- 2008 Sales of VEGF/R Antagonists
- VEGF-R Agonists
 - Cardiovascular Applications
 - Neurological Applications
- VEGF and VEGF-R Antagonists in Ophthalmology
- VEGF and VEGF-R Antagonists in Oncology
 - Avastin Pipeline
 - Biologics as VEGF and VEGF-R Antagonists
 - Small Molecules as VEGF RTK Inhibitors
 - Sutent Pipeline
 - Nexavar Pipeline
 - Selective VEGF RTK Inhibitors
 - Dual Target VEGF RTK Inhibitors
 - Triple Target VEGF RTK Inhibitors
 - Multi-Target VEGF RTK Inhibitors
 - Overview on RTK Inhibition Profiles of VEGF-R Inhibitors
- Corporate VEGF and VEGF-R Agonists and Antagonists
- About La Merie

Corporate VEGF/R Agonist and Antagonist R&D Pipelines

- Accelera
- ACT Biotech
- Advenchen Laboratories
- Affitech
- Allergan
- Allostera Pharma
- Alnylam Pharmaceuticals
- Amgen
- Ark Therapeutics
- AstraZeneca
- Attenuon

-- Aveo Pharmaceuticals
-- Bayer Schering-Pharma
-- Bio-Sidus
-- Boehringer Ingelheim
-- Bristol-Myers Squibb (BMS)
-- Cephalon
-- Chugai
-- Circadian
-- CSL
-- Cyclacell Pharmaceuticals
-- DxS
-- Edwards Lifesciences
-- Eisai
-- Eli Lilly
-- Epitomics
-- Ethical Oncology Sciences (EOS)
-- Exelixis
-- Eyetech
-- Genentech
-- GlaxoSmithKline (GSK)
-- Jubilant Innovation
-- Kringle Pharmaceuticals
-- Methylgen
-- Millennium
-- Molecular Partner
-- Nanogen Biopharmaceuticals
-- Neovacs
-- NeuroNova
-- Neurotech
-- Novartis
-- Onyx Pharmaceuticals
-- Opko
-- OSI Pharmaceuticals
-- Oxford BioMedica
-- Pepsan Systems
-- Pfizer
-- Pieris
-- PTC Therapeutics
-- Regeneron Pharmaceuticals
-- Roche
-- Sangamo Biosciences
-- Sanofi-aventis
-- Schering
-- SibTech
-- Sirna Therapeutics
-- Sopherion Therapeutics
-- Symphony Evolution
-- Takeda Pharmaceutical
-- Targa Therapeutics
-- Tekmira
-- Telik
-- Tigris Pharmaceuticals
-- Toolgen

- Trophogen
- VasGene
- ZymoGenetics

To order this report:

[Reportlinker Adds Competitor Analysis: VEGF and VEGF-R Agonists and Antagonists](#)

<http://www.reportlinker.com/p0154668/Reportlinker-Adds-Competitor-Analysis-VEGF-and-VEGF-R-Agonists-and-Antagonists>

[More market research reports here!](#)

CONTACT:

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker

Via PR Newswire - PRNewswire.co.uk

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

